YOLFTbeta
ADMA Biologics Inc

ADMA Biologics Inc

ADMA · NASDAQ · Healthcare / Biotechnology

13.68USD+0.44 (+3.32%)

Price History

Full chart

Market Stats

Previous Close13.24
Open13.29
Day Range13.07 – 14.02
52-Week Range7.21 – 20.46
Volume4.16M
Market Cap2.96B
P/E (TTM)18.87
Forward P/E11.22
EPS0.70
Dividend Yield0.00%
Beta0.66
50-Day Avg10.07
200-Day Avg10.86

About

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Adam S. Grossman
  • Employees640
  • Headquarters465 State Route 17, Ramsey, NJ, United States, 07446, USA
  • Websitehttps://www.admabiologics.com

Leadership

  • Mr. Adam S. GrossmanCo-Founder, President, CEO & Director · b. 1977
  • Dr. Jerrold B. Grossman D.P.S., Ph.D.Co-Founder & Vice Chairman of the Board · b. 1948
  • Mr. P. Terence KohlerCFO & Treasurer
  • Ms. Kaitlin M. KestenbergCOO & Senior VP of Compliance · b. 1987
  • Mr. Michael GoldsteinGeneral Counsel
  • Mr. John HaflExecutive Director of Sales
  • Mr. Skyler BloomSenior Director of Business Development & Corporate Strategy

Financials

Income Statement

Currency: USD2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue------1.12M3.07M5.92M7.18M10.66M22.76M16.99M29.35M42.22M80.94M154.08M258.21M426.45M510.17M
Growth (%)-------+174.35%+92.84%+21.34%+48.53%+113.49%-25.37%+72.79%+43.85%+91.72%+90.36%+67.59%+65.15%+19.63%
Cost of Revenue------669.06K2.02M3.74M4.31M6.36M29.16M42.19M39.50M61.29M79.77M118.81M169.27M206.90M217.41M
Gross Profit------449.06K1.04M2.17M2.87M4.30M-6.40M-25.21M-10.16M-19.07M1.17M35.27M88.94M219.55M292.76M
Gross Margin------40.16%34.04%36.74%39.93%40.34%-28.14%-148.42%-34.60%-45.17%1.45%22.89%34.44%51.48%57.39%
Operating Expense------8.36M16.09M18.19M18.38M21.63M32.91M35.08M31.27M45.84M59.55M74.63M67.31M80.57M101.32M
Operating Income-29.69M-29.69M-24.89M-20.01M-20.53K-26.46K-7.91M-15.04M-16.02M-15.51M-17.33M-39.31M-60.29M-41.42M-64.91M-58.37M-39.37M21.63M138.98M191.44M
Operating Margin-------707.36%-490.37%-270.79%-216.14%-162.56%-172.71%-354.95%-141.14%-153.75%-72.12%-25.55%8.38%32.59%37.53%
EBITDA--29.69M-24.89M-20.01M-20.53K-26.46K-7.71M-14.70M-15.83M-15.66M-16.81M-37.78M-56.77M-36.03M-59.82M-53.10M-39.51M5.12M147.69M197.86M
EBITDA Margin-------689.21%-479.15%-267.61%-218.14%-157.64%-165.99%-334.26%-122.76%-141.69%-65.60%-25.64%1.98%34.63%38.78%
Net Income-29.69M-29.69M-24.89M-20.01M-20.53K-26.46K-7.30M-15.53M-16.81M-17.97M-19.52M-43.76M-65.74M-48.28M-75.75M-71.65M-65.90M-28.24M197.67M146.93M
Net Income Margin-------653.00%-506.17%-284.22%-250.36%-183.05%-192.26%-387.06%-164.50%-179.41%-88.52%-42.77%-10.94%46.35%28.80%
R&D------3.47M9.30M9.52M7.02M7.69M6.23M3.93M2.34M5.91M3.65M3.61M3.30M1.81M4.76M
R&D as % of Total Revenue------310.26%303.27%160.88%97.75%72.12%27.37%23.11%7.99%13.99%4.50%2.35%1.28%0.43%0.93%
Interest Expense00000030.68K618.23K1.29M1.84M2.24M3.29M5.52M8.99M11.99M13.06M19.28M25.03M13.93M7.11M
Interest Expense % of Total Revenue------2.74%20.15%21.74%25.67%21.01%14.44%32.52%30.64%28.39%16.13%12.51%9.69%3.27%1.39%

Balance Sheet

Currency: USD2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets14.65M14.65M2.65M8.69M12.01K8.08K15.56M31.98M27.23M23.71M23.69M108.02M88.88M127.09M207.67M276.25M348.46M329.18M488.68M624.24M
Total Liabilities14.65M14.65M2.65M8.69M12.36K5.31K6.13M10.41M21.22M22.89M28.14M67.69M69.11M100.90M119.42M135.08M196.49M193.98M139.66M146.92M
Total Equity04.58M-13.31M-2.82M-3462.77K9.42M21.57M6.01M820.97K-4.46M40.33M19.77M26.19M88.25M141.17M151.97M135.21M349.02M477.32M
Cash14.65M14.65M2.65M8.69M12.01K8.08K12.54M26.15M17.20M10.44M9.91M43.11M22.75M26.75M55.92M51.09M86.52M51.35M103.15M87.63M
Total Debt10.07M10.07M15.96M11.51M7.20M9.82M3.97M5.08M14.97M15.77M20.26M42.97M44.22M84.73M97.67M102.92M154.44M141.42M82.12M79.89M
Net Debt-4.58M-4.58M13.31M2.82M7.19M-8.08K-8.57M-21.07M-2.23M5.33M10.34M-136.72K21.47M57.98M41.75M51.83M67.92M90.07M-21.03M-7.75M

Cash Flow

Currency: USD2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-23.61M-23.61M-19.00M-24.46M-19.68K-29.00K-6.90M-10.89M-14.70M-15.42M-18.27M-37.27M-62.68M-76.19M-102.00M-112.37M-59.51M8.80M118.67M50.40M
Investing Cash Flow-------118.85K-3.13M-4.04M-1.74M904.58K15.21M-2.10M-3.81M-12.72M-13.51M-13.91M-4.98M-8.57M-21.89M
Financing Cash Flow12.50M12.50M7.00M30.50M23.00K25.50K19.47M27.63M9.80M10.40M16.84M60.75M42.92M80.00M143.90M121.05M108.85M-38.99M-58.30M-44.02M
Capital Expenditure000000118.85K196.63K2.32M26.07K73.41K2.68M2.10M3.81M12.73M13.51M13.91M4.98M8.57M22.57M
Free Cash Flow-23.61M-23.61M-19.00M-24.46M-19.68K-29.00K-7.02M-11.08M-17.03M-15.44M-18.34M-39.95M-64.77M-80.01M-114.73M-125.88M-73.42M3.82M110.10M27.82M
Dividends Paid------3.91M00000---61.60K2.90M---
FCF to OCF100.00%100.00%100.00%100.00%100.00%100.00%101.72%101.81%115.80%100.17%100.40%107.18%103.34%105.00%112.48%112.02%123.38%43.40%92.77%55.20%
Dividend Paid to FCF-------55.62%0.00%0.00%0.00%0.00%0.00%----0.05%-3.95%---

Earnings

Report DateNov 12, 2013Mar 28, 2014May 12, 2014Aug 11, 2014Nov 10, 2014Mar 9, 2015May 12, 2015Aug 11, 2015Nov 10, 2015Mar 23, 2016May 13, 2016Aug 12, 2016Nov 10, 2016Feb 24, 2017May 12, 2017Aug 11, 2017Nov 3, 2017Mar 5, 2018May 14, 2018Aug 10, 2018Nov 8, 2018Mar 13, 2019May 8, 2019Aug 8, 2019Nov 6, 2019Mar 12, 2020May 6, 2020Aug 5, 2020Nov 5, 2020Mar 25, 2021May 12, 2021Aug 11, 2021Nov 10, 2021Mar 24, 2022May 11, 2022Aug 10, 2022Nov 9, 2022Mar 23, 2023May 10, 2023Aug 9, 2023Nov 8, 2023Feb 28, 2024May 9, 2024Aug 8, 2024Nov 7, 2024Feb 26, 2025May 7, 2025Aug 6, 2025Nov 5, 2025Mar 19, 2026May 6, 2026Aug 5, 2026Nov 4, 2026
EPS Estimate--0.47-0.55-0.52-0.32-0.38-0.43-0.38-0.37-0.43-0.37-0.38-0.42-0.31-0.28-0.22-0.45-0.31-0.31-0.33-0.33-0.33-0.32-0.31-0.22-0.17-0.11-0.16-0.19-0.16-0.16-0.15-0.14-0.09-0.08-0.08-0.07-0.06-0.04-0.02-0.010.020.060.080.130.140.170.140.160.190.200.160.19
EPS Actual-0.29-0.54-0.64-0.43-0.36-0.38-0.37-0.37-0.48-0.44-0.43-0.50-0.34-0.34-0.51-0.55-0.59-0.29-0.39-0.35-0.33-0.39-0.32-0.25-0.19-0.18-0.26-0.23-0.19-0.20-0.16-0.14-0.13-0.09-0.09-0.07-0.08-0.06-0.03-0.020.010.040.080.130.150.140.110.140.160.220.170.160.22
Surprise--14.89%-16.36%17.31%-12.50%0.00%13.95%2.63%-29.73%-2.33%-16.22%-31.58%19.05%-9.68%-82.14%-150.00%-31.11%6.45%-25.81%-6.06%0.00%-18.18%0.00%19.35%13.64%-5.88%-136.36%-43.75%0.00%-25.00%0.00%6.67%7.14%0.00%-12.50%12.50%-14.29%0.00%25.00%0.00%200.00%100.00%33.33%62.50%15.38%-6.21%-35.29%0.00%0.00%15.53%-15.00%0.00%15.79%
Timing--After-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap2.96B
Enterprise Value2.56B
Trailing P/E18.87
Forward P/E11.22
PEG Ratio0.00
Price / Sales5.78
Price / Book6.10
EPS0.70
Book Value2.01
Revenue (TTM)512.28M
Gross Profit (TTM)331.47M
EBITDA224.19M
Profit Margin32.98%
Operating Margin42.16%
Return on Equity41.90%
Return on Assets21.78%
Shares Outstanding223.98M
Shares Float219.66M
Beta0.66
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 4 analystsTarget 17.00
  • Strong Buy
    2
  • Buy
    1
  • Hold
    1

Ownership Breakdown

Institutions
92.71%
Insiders
1.97%
Retail / Other
5.32%

Top Institutional Holders

  • BlackRock Inc
    38.36M17.12%
  • State Street Corp
    17.12M7.64%
  • Vanguard Capital Management, LLC
    10.10M4.51%
  • Vanguard Portfolio Management, LLC
    10.09M4.50%
  • Rubric Capital Management LP
    9.34M4.17%
  • Capital Research Global Investors
    8.76M3.91%
  • First Trust Advisors L.P.
    7.80M3.48%
  • Geode Capital Management, LLC
    6.06M2.71%
  • Caligan Partners LP
    5.73M2.56%
  • D. E. Shaw & Co LP
    5.27M2.35%
  • Nantahala Capital Management, LLC
    4.72M2.11%
  • Dimensional Fund Advisors, Inc.
    3.61M1.61%
  • The Goldman Sachs Group Inc
    3.51M1.57%
  • B Group, Inc
    3.26M1.46%

Top Fund Holders

  • iShares Core S&P Small-Cap ETF
    13.42M5.99%
  • First Trust NYSE Arca Biotech ETF
    9.45M4.22%
  • American Funds SMALLCAP World A
    8.52M3.81%
  • Vanguard MStar Total Stk Mkt Idx Invest
    6.52M2.91%
  • iShares Russell 2000 ETF
    5.84M2.61%
  • State Street® SPDR® S&P® Biotech ETF
    4.74M2.12%